» Articles » PMID: 14754783

Randomized Clinical Trial of Supervised Tapering and Cognitive Behavior Therapy to Facilitate Benzodiazepine Discontinuation in Older Adults with Chronic Insomnia

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2004 Feb 3
PMID 14754783
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study evaluated the effectiveness of a supervised benzodiazepine taper, singly and combined with cognitive behavior therapy, for benzodiazepine discontinuation in older adults with chronic insomnia.

Method: Seventy-six older adult outpatients (38 women, 38 men; mean age of 62.5 years) with chronic insomnia and prolonged use (mean duration of 19.3 years) of benzodiazepine medication for sleep were randomly assigned for a 10-week intervention consisting of a supervised benzodiazepine withdrawal program (N=25), cognitive behavior therapy for insomnia (N=24), or supervised withdrawal plus cognitive behavior therapy (N=27). Follow-up assessments were conducted at 3 and 12 months. The main outcome measures were benzodiazepine use, sleep parameters, and anxiety and depressive symptoms.

Results: All three interventions produced significant reductions in both the quantity (90% reduction) and frequency (80% reduction) of benzodiazepine use, and 63% of the patients were drug-free within an average of 7 weeks. More patients who received medication taper plus cognitive behavior therapy (85%) were benzodiazepine-free after the initial intervention, compared to those who received medication taper alone (48%) and cognitive behavior therapy alone (54%). The patients in the two groups that received cognitive behavior therapy perceived greater subjective sleep improvements than those who received medication taper alone. Polysomnographic data showed an increase in the amount of time spent in stages 3 and 4 sleep and REM sleep and a decrease in total sleep time across all three conditions from baseline to posttreatment. Initial benzodiazepine reductions were well maintained up to the 12-month follow-up, and sleep improvements became more noticeable over this period. No significant withdrawal symptoms or adverse events were associated with benzodiazepine tapering.

Conclusions: A structured, time-limited intervention is effective in assisting chronic users of benzodiazepine medication to discontinue or reduce their use of medication. The addition of cognitive behavior therapy alleviates insomnia, but sleep improvements may become noticeable only after several months of benzodiazepine abstinence.

Citing Articles

Poststroke Anxiety: The Other Poststroke Mood Disorder.

MacKenzie J, Moreno-Gomez V Stroke. 2024; 55(11):2703-2704.

PMID: 39417252 PMC: 11774476. DOI: 10.1161/STROKEAHA.124.048771.


Integrating the Memory Support Intervention into the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C): can improving memory for treatment in midlife and older adults improve patient outcomes? Study protocol for a randomized....

Milner A, Hache R, Oliver S, Sarfan L, Spencer J, Cogan A Trials. 2024; 25(1):650.

PMID: 39363383 PMC: 11448292. DOI: 10.1186/s13063-024-08468-0.


Benzodiazepine Discontinuation and Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy.

Maust D, Petzold K, Strominger J, Kim H, Bohnert A JAMA Netw Open. 2023; 6(12):e2348557.

PMID: 38117495 PMC: 10733804. DOI: 10.1001/jamanetworkopen.2023.48557.


Perspectives on increasing the impact and reach of CBT-I.

Manber R, Simpson N, Gumport N Sleep. 2023; 46(12).

PMID: 37903637 PMC: 10710991. DOI: 10.1093/sleep/zsad168.


Impact of a deprescribing tool on the use of sedative hypnotics among older patients: study protocol for a cluster randomised controlled trial in Swiss primary care (the HYPE trial).

Weiss K, Pichierri G, Grischott T, Groth S, Neuner-Jehle S BMJ Open. 2023; 13(9):e075828.

PMID: 37730388 PMC: 10510907. DOI: 10.1136/bmjopen-2023-075828.